EB-612
Hypoparathyroidism
Phase 2Active
Key Facts
About Extend Biosciences
Extend Biosciences is a private, clinical-stage biotech leveraging its proprietary Half-life Extension Platform (HLEP) to create improved peptide and protein therapeutics. The company's core innovation involves conjugating drug candidates to a vitamin D derivative, which binds to serum vitamin D binding protein (DBP), creating a circulating reservoir that extends half-life from hours to days or weeks. Its most advanced candidate, EB-612, is a once-weekly PTH analog for hypoparathyroidism that has completed a Phase 2a study. The platform has potential applications across multiple metabolic and endocrine disorders with high unmet need.
View full company profileTherapeutic Areas
Other Hypoparathyroidism Drugs
| Drug | Company | Phase |
|---|---|---|
| Palopegteriparatide (TransCon PTH) | VISEN Pharmaceuticals | Phase 3 |
| Oral Long-Acting PTH Tablet | Opko Health | Preclinical |
| Hypoparathyroidism Program | Confo Therapeutics | Discovery |
| Canvuparatide (MBX 2109) | MBX Biosciences | Phase 2 |
| SEP-479 (PTH1R) | Septerna | Phase 2 |
| EB612 (oral PTH(1-34)) | Entera Bio | Phase 2 |
| Oral Long-Acting PTH | Entera Bio | Discovery/Preclinical |